Platform Guides

    Kalshi Launches Clinical Trial Prediction Markets: Drug Development Gets Its First Public Odds

    Kalshi and AppliedXL launched 13 regulated prediction markets on clinical trial outcomes and FDA drug approval decisions on July 16, 2026 — making drug-development odds publicly available for the first time.

    By Prediction Markets US Guides DeskTuesday, July 21, 20269 min read
    Kalshi Launches Clinical Trial Prediction Markets: Drug Development Gets Its First Public Odds

    For decades, the odds that a drug would succeed or fail were among the most valuable — and most hidden — numbers in the economy. Banks and hedge funds paid for private research; pharma executives held the numbers close. The rest of the world guessed.

    That changed on July 16, 2026, when Kalshi, a CFTC-regulated financial exchange, announced a partnership with public intelligence company AppliedXL to launch the first regulated prediction markets on clinical trial outcomes and FDA drug approval decisions.

    The result: 13 contracts where anyone can now see — and trade — a continuously updated public probability on whether a specific drug will win approval or meet its trial endpoint.

    What Kalshi Launched

    Kalshi and AppliedXL opened 13 contracts covering more than a dozen FDA regulatory decisions and late-stage clinical trials, across some of the most closely watched drug programs in medicine. The debut slate includes:

    • Will the FDA approve Gilead/Arcellx's anito-cel for relapsed/refractory multiple myeloma?
    • Will AR1001's POLARIS-AD Phase 3 trial meet its primary endpoint in early Alzheimer's disease? (AriBio)
    • When will Eli Lilly's retatrutide receive FDA approval? (the next-generation weight-loss drug)
    • Markets on drugs from Summit Therapeutics (ivonescimab, lung cancer) and Sanofi

    Within the first day of trading, more than $100,000 had already been wagered across the contracts, according to Forbes.

    The joint venture extends Kalshi's existing position as a CFTC-regulated Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO) into entirely new territory — bringing the same regulatory framework that governs its election and weather contracts to the $2.3 trillion pharmaceutical development industry.

    Live price — will the FDA approve Retatrutide this year?

    How the Markets Work

    The design of Kalshi's clinical trial markets centers on one principle: every resolution must trace back to a named public document, and that document's reading criteria must be locked before trading begins.

    Three resolution sources: Each contract specifies one of three public documents as its resolution anchor:

    1. The registered primary endpoint on ClinicalTrials.gov — the main result the trial was designed to measure, agreed upon and registered publicly before results arrive
    2. The FDA approval letter for regulatory-decision contracts
    3. The advisory committee voting record, when the FDA's expert panel vote determines the outcome

    AppliedXL, the company's resolution partner, defines exactly how that document will be read before any contract opens for trading. This pre-commitment prevents the ambiguity that plagued earlier informal prediction markets — there's no post-hoc dispute about what a trial "really showed."

    "Clinical trial results are rarely handed to you cleanly," said Francesco Marconi, AppliedXL's CEO. "They come out in pieces, scattered across registries, regulatory filings, and company statements, and the press releases often put a favorable spin on what the data actually shows. Resolving a market means reconciling all of that back to the primary source, which is what we built AppliedXL to do."

    Kalshi retains sole and final authority over every market outcome under its exchange rules. AppliedXL serves as the independent resolution-analysis partner — it submits findings and supporting evidence, but Kalshi independently reviews the record and makes the final determination.

    The Scope: Late-Stage Trials Only

    The pilot is deliberately narrow. Two design constraints govern what can be listed:

    1. Phase 3 / late-stage trials only. Early-phase trials have exploratory endpoints and greater insider trading risk. Phase 3 trials register their primary endpoints publicly with the FDA in advance, making resolution unambiguous. Kalshi will not list contracts on Phase 1 or Phase 2 trials under the current pilot.

    2. Contracts list only after enrollment closes. A visible market price could influence physician referral patterns and patient recruitment. By waiting until enrollment closes before opening a market, Kalshi eliminates the possibility that a doctor's awareness of a trade could affect who gets into a trial.

    Most contracts at launch focus on late-stage trials run by established biopharma companies with market capitalizations of at least $500 million, according to Forbes.

    Live Market: Gilead's Anito-cel

    Live price — FDA decision on anito-cel (Gilead Sciences) for multiple myeloma:

    Why Drug Development Needed This

    The pharmaceutical industry has an information problem. The average cost to bring a single drug to market is an estimated $2.3 billion, according to McKinsey — and a company's fortunes can turn on a single trial result. Yet the probability estimates that inform those multi-billion-dollar decisions stay locked behind closed doors.

    "The odds that a drug will succeed are among the most valuable numbers in the economy, and among the least visible," Kalshi CEO Tarek Mansour wrote in the launch announcement. "Banks, expert networks, and pharmaceutical companies all produce estimates, but they stay behind closed doors."

    The incomplete public record makes the problem worse. As of April 2026, the FDA reported that 29.6% of studies it considered highly likely to be subject to mandatory reporting requirements had no results information submitted to ClinicalTrials.gov — meaning roughly 30% of trials that were legally required to post results hadn't done so.

    Kalshi's case: a publicly listed contract produces a "continuously updated public probability that reflects the weight of the evidence rather than the preferred messaging of the trial sponsor." People who were never in the room — investors, smaller developers, clinicians, and patients — can all read the same number.

    The CFTC, which regulates Kalshi, has signaled interest in this direction. CFTC Chair Michael Selig has publicly touted drug-trial prediction markets as a potential mechanism for patients in need of specific medicines to hedge their future treatment costs, according to Bloomberg.

    Safeguards Against Insider Trading

    The biomedical context raised immediate concerns about insider trading and conflicts of interest. The pilot addresses three specific risks:

    Employment verification. Kalshi will require employment verification for all traders in these markets — an extra layer beyond its standard account verification. Anyone who works at a company with material nonpublic information about a listed trial is explicitly prohibited from trading.

    Enrollment closure gate. As described above, markets open only after enrollment closes, preventing recruiting-stage manipulation.

    Pre-committed resolution criteria. Because AppliedXL defines how the source document will be read before any market opens, there is no mechanism by which a sponsor's press release framing can change the resolution outcome. The contract resolves on the primary endpoint as registered, not on the company's characterization of its data.

    Whether these safeguards are sufficient is an open question. STAT News reported that researchers and healthcare providers raised concerns that financial incentives attached to trial outcomes could have downstream effects on reporting behavior — particularly selective reporting of secondary endpoints or timing of result publications.

    What This Means for Biotech Investors

    For investors, the practical case is straightforward: drug stocks are blunt instruments. Owning Gilead equity means owning exposure to management, cash, pipeline, macro conditions, and dozens of other drugs simultaneously. The anito-cel approval contract prices only the anito-cel question.

    "An investor can be right about the science or the regulatory outcome and still watch the stock move the other way," Kalshi wrote in the launch announcement. "These contracts isolate the single question."

    Shorter-term, the contracts offer a hedging tool: a biotech investor with a long Gilead position can short the approval contract as a hedge against a negative FDA decision, without needing to unwind their equity position.

    Kalshi also published a joint whitepaper with AppliedXL — "Biopharma's Public Probability: The State and Future of Prediction Markets in Drug Development" — which examines the information these markets can produce, the risks they raise, and the standards required for them to function responsibly.

    Track the Markets at PredictionMarkets.US

    PredictionMarkets.US is tracking the full suite of Kalshi clinical trial and FDA approval markets alongside its existing coverage of event contracts across elections, sports, and economics.

    As these markets evolve — and as more contracts are added beyond the initial 13 — the site will aggregate current prices, volume data, and context in one place.

    FAQ

    Are these markets legal? Yes. Kalshi is a CFTC-designated contract market (DCM) and derivatives clearing organization (DCO). It operates under the same regulatory framework as other Kalshi contracts. The clinical trial markets were designed in coordination with bioethicists, biopharma professionals, and investors to meet CFTC requirements.

    Can anyone trade these markets? Kalshi's standard eligibility requirements apply, plus an additional employment verification layer. Anyone with material nonpublic information about a listed trial is explicitly prohibited from participating.

    What happens if a trial is discontinued early? Contract resolution procedures address discontinuation scenarios. Each contract specifies its resolution source and criteria — discontinuation or withdrawal typically triggers a defined resolution path under the contract terms.

    How are the odds calculated? Prices are set by trading activity, not by Kalshi or AppliedXL. A contract trading at $0.72 reflects approximately a 72% market-implied probability based on current trading — the same mechanism as all Kalshi event contracts.

    Will this expand beyond 13 drugs? Kalshi has described the program as a pilot with the intention to expand. The scope may grow to include additional Phase 3 trials and potentially other types of regulatory decisions over time.

    Sources & Verification

    Back to Articles